Skip to content
ApprovedFDA approved

Bromocriptine (Parlodel)

Prescription dopamine-like drug that lowers prolactin and that bodybuilders also use; may cause nausea and low blood pressure.

Available at

The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

Bromocriptine (Parlodel) vial

DETAILED OVERVIEW

What is Bromocriptine (Parlodel)?

Bromocriptine (Parlodel) is a prescription medicine that imitates the action of dopamine and lowers the production of the hormone prolactin. It is approved for treating excess prolactin and is also used as an add-on treatment in Parkinson's disease, and a quick-release version is approved for type 2 diabetes. Bodybuilders also use it off-label to control prolactin during steroid use.

The most common side effects are nausea and vomiting; a drop in blood pressure on standing, dizziness and fainting also occur. As a drug that acts on dopamine it can cause compulsive gambling or shopping, hypersexuality, binge eating, sudden falling asleep, confusion or hallucinations. Ergot-derived drugs can constrict blood vessels, and after long-term use scarring of the heart valves and lungs can develop. In pregnancy it may be used only with a strict medical indication; it blocks milk production and can restore fertility.

Mechanism

First-gen ergot D1+D2 mixed DA agonist, prolactin suppression + secondary T2DM insulin sensitivity boost

Half-life

~3-12 hours

Onset

Prolactin reduction 1-2 h, plateau 8-24 h

Legal status

FDA + EMA Rx, HU + PL approved, WADA allowed

Data console

Lab data

Androgenic:AnabolicN/A (not AAS)
AR bindingD2 Ki ~5 nM, D1 ~30-50 nM (mixed agonist). Pancreatic…
Active half-life~3-12 hours (parent compound active)
Detection windowNot relevant (WADA not listed).
AromatizationNone – DA agonist.
HepatotoxicityLow hepatic; cardiac valvulopathy risk similar to cabergoline at high dose; less commonly documented in AAS-PCT context.

Safety

Side effects, stop signs, contraindications

Side effects · 8

  • Nausea and vomiting (the most common effect, in a majority of patients), especially at the start of titration; mitigated by taking with food and slow dose escalation.
  • Orthostatic (postural) hypotension, dizziness, fainting, especially after the first doses; rise slowly from sitting or lying.
  • Headache, fatigue, nasal congestion and abdominal discomfort, vegetative accompaniments of the ergot-dopaminergic effect.
  • Impulse-control disorders (compulsive gambling, shopping, hypersexuality, binge eating) plus daytime somnolence or sudden sleep onset, a class effect of dopamine agonists.
  • Psychiatric symptoms at higher doses: confusion, hallucinations, dyskinesia (involuntary movements), agitation; usually dose-dependent and reversible on stopping.
  • Raynaud-like peripheral vasospasm, coldness and digital discoloration; rarely severe, an ergot-class vasoconstrictive effect.
  • With chronic high-dose use (Parkinson-protocol level) fibrotic complications: cardiac valve fibrosis, retroperitoneal and pleuropulmonary fibrosis; low at PCT doses, but annual echocardiography is warranted with prolonged use.
  • Cycloset (quick-release 0.8 mg morning) form: milder vegetative profile, but nausea, fatigue and hypotension can still occur, especially combined with antihypertensives.

Contraindications · 7

  • Uncontrolled hypertension, hypertensive disorders of pregnancy, eclampsia or preeclampsia history, and severe ischemic heart disease, because ergot vasospasm is dangerous (the postpartum indication was withdrawn for this reason).
  • Ergot-alkaloid hypersensitivity (e.g. ergotamine, methylergometrine, other ergot derivatives) due to cross-allergy.
  • Co-administration with antipsychotics (D2 antagonists) and other dopamine blockers (e.g. metoclopramide): mutually antagonistic effect, so antiemesis must NOT use metoclopramide.
  • Impulse-control disorder, uncontrolled psychosis or significant psychiatric history, because the dopamine agonist can worsen them (also caution if ICD occurred on Cabergoline).
  • Severe hepatic or renal impairment, because CYP3A4 metabolism and clearance are disturbed and drug levels can rise.
  • Together with strong CYP3A4 inhibitors (macrolide antibiotics, azole antifungals, protease inhibitors): bromocriptine levels and toxicity rise, requiring dose reduction or avoidance.
  • Pregnancy and breastfeeding: prolactin suppression inhibits lactation, and in pregnancy use only on strict indication; it can restore fertility, so unintended conception may occur.

Related Performance Compounds

Same therapeutic category

Studies

Related research and clinical findings

Telegram

Have a question about Bromocriptine (Parlodel)?

Reach out to an advisor on Telegram. Performance compounds are presented with a harm-reduction approach, based on peer-reviewed evidence.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 14, 2026

The information here is for educational and scientific purposes only. Performance-enhancing compounds (AAS, prohormones, stimulants, doping agents) are illegal without prescription in Hungary and most of the EU, and carry serious health and legal risks. WADA bans them in competitive sport. This is NOT a usage guide, and we do not encourage any illegal use. If you do use them, medical supervision and regular bloodwork are ESSENTIAL. Severe endocrine, cardiovascular, hepatic and psychiatric side effects are possible.